Ms. Chrousos currently serves as the Chief Strategy Officer of The Libra Group, where she leads a wide range of strategic initiatives spanning technology transformation to operational development. Headquartered in New York and London, The Libra Group is a diverse, international business group that is active in 35 countries and focused on six business areas: aviation, energy, hospitality, real estate, shipping, and diversified investments. Immediately prior to being appointed Chief Strategy Officer, Ms. Chrousos served as the group's Chief Innovation Officer. Previously, Ms. Chrousos served as a political appointee for the Obama Administration in various roles, including as an Associate Administrator for the General Services Administration. In this capacity, Ms. Chrousos led the Office of Citizen Services and 18F, a digital services team that implemented online service delivery projects and open data initiatives at more than a dozen agencies, including NIH, HHS and the VA. Prior to her departure from the Administration, Ms. Chrousos helped found the Technology Transformation Service, which serves as a foundation for the government's ongoing digital transformation; she served as its Founding Commissioner. Prior to entering public service, Ms. Chrousos co-founded and led two companies, including HealthLeap, a health tech company that reimagined the way doctors and patients communicate. HealthLeap was acquired by Vitals.com 10 months after its launch. She also has several years of consulting experience with The Boston Consulting Group and The World Bank. Ms. Chrousos sits on several non-profit boards, including that of a maternal mental health foundation, and was twice named one of the Federal Government's '50 Women in Technology' by FedScoop and one of Greece's '40 under 40' by Fortune Magazine. Ms. Chrousos holds a B.A. from Georgetown University, an MSc from The London School of Economics and Political Science, and an M.B.A. from Columbia Business School.
What is Phaedra Chrousos' net worth?
The estimated net worth of Phaedra Chrousos is at least $61,523.00 as of June 14th, 2021. Ms. Chrousos owns 12,925 shares of Vanda Pharmaceuticals stock worth more than $61,523 as of December 18th. This net worth evaluation does not reflect any other investments that Ms. Chrousos may own. Learn More about Phaedra Chrousos' net worth.
How do I contact Phaedra Chrousos?
Has Phaedra Chrousos been buying or selling shares of Vanda Pharmaceuticals?
Phaedra Chrousos has not been actively trading shares of Vanda Pharmaceuticals during the last quarter. Most recently, Phaedra Chrousos sold 2,075 shares of the business's stock in a transaction on Monday, June 14th. The shares were sold at an average price of $19.34, for a transaction totalling $40,130.50. Following the completion of the sale, the director now directly owns 12,925 shares of the company's stock, valued at $249,969.50. Learn More on Phaedra Chrousos' trading history.
Who are Vanda Pharmaceuticals' active insiders?
Are insiders buying or selling shares of Vanda Pharmaceuticals?
In the last twelve months, insiders at the biopharmaceutical company sold shares 2 times. They sold a total of 7,251 shares worth more than $39,175.92. The most recent insider tranaction occured on November, 14th when Director Stephen Ray Mitchell sold 5,000 shares worth more than $25,850.00. Insiders at Vanda Pharmaceuticals own 8.9% of the company.
Learn More about insider trades at Vanda Pharmaceuticals. Information on this page was last updated on 11/14/2024.
